Asset Details
Do you wish to reserve the book?
Do skin bacteriostatic agents reduce acute radiodermatitis in breast cancer patients? A prospective interventional study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Do skin bacteriostatic agents reduce acute radiodermatitis in breast cancer patients? A prospective interventional study
Do you wish to request the book?
Do skin bacteriostatic agents reduce acute radiodermatitis in breast cancer patients? A prospective interventional study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Do skin bacteriostatic agents reduce acute radiodermatitis in breast cancer patients? A prospective interventional study
2025
Overview
Radiodermatitis is the most prevalent complication in breast cancer patients undergoing radiotherapy. Emerging evidence suggests a correlation between radiodermatitis and Staphylococcus aureus colonization. The aim of our study was to explore whether the application of skin bacteriostatic agents (a sterile liquid dressing containing fucoidan oligosaccharides with anti-Staphylococcus aureus activity) could mitigate acute radiodermatitis in breast cancer patients.
We conducted a prospective interventional study, enrolling breast cancer patients receiving outpatient radiotherapy at our institution from July 1, 2023, to January 31, 2024. Patients were divided into an experimental group and a control group based on the usage of skin bacteriostatic agents. The first outcome was evaluated using the Radiation Therapy Oncology Group (RTOG) criteria. The second outcome was the patient's reported symptoms of radiodermatitis, which included itching, pain, tightness, burning and swelling. The third outcome was whether the usage of skin bacteriostatic agents delayed the onset of self-reported radiodermatitis symptoms.
A total of 183 patients were enrolled, comprising 101 breast-conserving patients (21 in the experimental group, 80 in the control group); and 82 mastectomy patients (26 in the experimental group, 56 in the control group). The experimental group showed a significantly lower grade of radiodermatitis compared to the control group in both breast-conserving and mastectomy patients (P < 0.05). Patient-reported symptoms of radiodermatitis included itching (54.6%), pain (48.1%), tightness (21.9%), burning (11.5%), and swelling (17.5%), but there was no difference between the two groups and onset in radiodermatitis. Further analysis indicated that hypofractionated radiotherapy could reduce the severity of radiodermatitis and itchiness.
Skin bacteriostatic agents used during radiotherapy can reduce the severity of radiodermatitis in breast cancer patients, although it does not alleviate self-reported symptoms of dermatitis. Hypofractionated radiotherapy is recommended to reduce the severity of radiodermatitis.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Aged
/ Anti-Bacterial Agents - administration & dosage
/ Anti-Bacterial Agents - therapeutic use
/ Breast Neoplasms - radiotherapy
/ Burning
/ Complications and side effects
/ Female
/ Fucoidan
/ Humans
/ Itching
/ Medicine and Health Sciences
/ Pain
/ Patients
/ Pruritus
/ Radiodermatitis - drug therapy
/ Radiodermatitis - prevention & control
/ Research and Analysis Methods
/ Skin
/ Staphylococcus aureus - drug effects
/ Swelling
/ Toxicity
We currently cannot retrieve any items related to this title. Kindly check back at a later time.